Close Menu
Anita Kohli, MD

Assistant Professor

Contact

School of Medicine

Anita Kohli, MD

Assistant Professor

Department

Medicine (Phoenix)

Position

Assistant Professor

Publications

  • Journal of hepatology
    Yuen Man-Fung, WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
    80, p. S809 - S810 2024
  • Journal of hepatology
    Dale Kelly, WED-151 Routine cholestasis genetic testing in patients with intrahepatic cholestasis of pregnancy reveals high prevalence of genetic variants of bile acid transport defects
    80, p. S709 - S710 2024
  • The American journal of gastroenterology
    Leff Phillip, S3496 A Rare Case of Non-Cirrhotic Portal Hypertension Caused by Necrobiotic Xanthogranuloma
    118:10S, p. S2296 - S2296 2023
  • Open forum infectious diseases
    Shapiro Adrienne E, Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Non-inferiority Clinical Trial 2023
  • Journal of hepatology
    Yuen Man-Fung, LBP-38 - Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
    78, p. S125 - S125 2023
  • Journal of hepatology
    Alkhouri Naim, FRI-525 - The effects of a novel online app (Noom Weight) on weight loss and liver biomarkers in patients with NAFLD: a single arm proof-of-concept study
    78, p. S828 - S828 2023
  • Journal of hepatology
    Alkhouri Naim, SAT-488 - LIVERFASt GP+ (GP+), a non-invasive blood testing for NAFLD staging, improves risk stratification of patients with indeterminate FIB-4 results
    78, p. S711 - S711 2023
  • Hepatology communications
    Noureddin Mazen, Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+and 4 scores
    7:5 2023
  • Hepatology (Baltimore, Md.)
    Chang Devon, Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis
    77:2, p. 546 - 557 2023
  • Clinical gastroenterology and hepatology
    Lawitz Eric J., Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
    21:1, p. 143 - 152.e3 2023
  • Journal of hepatology
    Alkhouri Naim, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
    77:3, p. 607 - 618 2022
  • Journal of hepatology
    Noureddin Mazen, The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH
    77, p. S427 2022
  • The lancet. Gastroenterology & hepatology
    Harrison Stephen A., Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
    7:7, p. 603 - 616 2022
  • Gastroenterology (New York, N.Y. 1943)
    Leff Phillip, Tu1311: EXTERNAL VALIDATION OF THE AGILE3+ SCORE AS A PREDICTOR OF ADVANCED FIBROSIS IN A COHORT OF U.S. ADULTS WITH BIOPSYPROVEN NAFLD
    162:7, p. S-1271 2022
  • The American journal of gastroenterology
    Harrison Stephen A., Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
    116:12, p. 2399 - 2409 2021
  • Nature communications
    Harrison Stephen A., A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
    12:1, p. 5503 - 5503 2021
  • American journal of preventive cardiology
    Baum Seth J., LIVRQNac (AXA1125) ENHANCES INSULIN SENSITIVITY IN PRIMARY HUMAN HEPATOCYTES AND IN SUBJECTS WITH NAFLD AND T2D
    7, p. 100263 2021
  • Hepatology communications
    Younossi Zobair M., Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
    5:7, p. 1201 - 1211 2021
  • Diabetes (New York, N.Y.)
    Baum SETH, 752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D
    70:Supplement_1 2021
  • Hepatology (Baltimore, Md.)
    Loomba Rohit, Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
    73:2, p. 625 - 643 2021
  • Gastroenterology (New York, N.Y. 1943)
    Harrison Stephen A., Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
    160:1, p. 219 - 231.e1 2021
  • Hepatology (Baltimore, Md.)
    Alkhouri Naim, Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic
    72:5, p. 1509 - 1513 2020
  • The American journal of gastroenterology
    Aggarwal Pankaj, S1025 The Effects of Age on the Accuracy of the FAST Score to Predict the Presence of NASH With Significant Fibrosis
    115:1, p. S522 - S522 2020
  • The American journal of gastroenterology
    Aggarwal Pankaj, S1024 Evaluation of the FAST Score in Patients With Nonalcoholic Fatty Liver Disease and High Liver Stiffness Measurements
    115:1, p. S522 - S522 2020
  • The American journal of gastroenterology
    Aggarwal Pankaj, S3286 Identifying Patients With Metabolic Syndrome Who Require Pharmacotherapy for Nonalcoholic Steatohepatitis (NASH) Using the FAST Score
    115:1, p. S1715 - S1715 2020
  • The American journal of gastroenterology
    Aggarwal Pankaj, S1190 Identifying Patients With Type 2 Diabetes Mellitus Who Require Pharmacotherapy for Nonalcoholic Steatohepatitis (NASH) Using the FAST Score
    115:1, p. S595 - S595 2020
  • Journal of hepatology
    Harrison Stephen A., LBO01 - Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
    73, p. S114 - S115 2020
  • Journal of hepatology
    Harrison Stephen A., LBP01 - Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (
    73, p. S123 - S123 2020
  • Journal of hepatology
    Loomba Rohit, LBO04 - Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
    73, p. S116 - S117 2020
  • Liver international
    Pockros Paul J., CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
    39:11, p. 2082 - 2093 2019
  • Open forum infectious diseases
    Mera Jorge, Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives
    6:7, p. ofz128 - ofz128 2019
  • Hepatology communications
    Shrivastava Shikha, Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus
    2:12, p. 1451 - 1466 2018
  • Journal of Viral Hepatitis
    Shrivastava S., Augmentation of Hepatitis C Virus-Specific Immunity and Sustained Virologic Response
    24:9, p. 742 - 749 2017
  • Hepatology communications
    Meissner Eric G., Rapid changes in peripheral lymphocyte concentrations during interferon‐free treatment of chronic hepatitis C virus infection
    1:7, p. 586 - 594 2017
  • Scientific reports
    Nguyen Thi Huyen Tram, The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
    7:1, p. 10233 - 10233 2017
  • Journal of acquired immune deficiency syndromes (1999)
    Wilson Eleanor, P-C8 Directly acting antiviral therapies have differential effects on cellular and soluble markers of inflammation in success-fully-treated HIV/HCV co-infected patients
    74, p. 80 2017
  • Journal of acquired immune deficiency syndromes (1999)
    Rosenthal Elana, P-C13 Impact of HIV status, HCV genotype, and number of DAAs on HCV viral kinetics in patients with HCV genotype 1 receiving DAA therapy
    74, p. 82 2017
  • World journal of hepatology
    Tang Lydia Shuk Yee, Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment
    8:31, p. 1318 - 1326 2016
  • Therapeutic advances in gastroenterology
    Kohli Anita, Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease
    9:6, p. 887 - 897 2016
  • Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America
    Kattakuzhy S., Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease
    62:4, p. 440 - 447 2016
  • Clinics in Liver Disease
    Joshi Kartik, Alcoholic Liver Disease: High Risk Or Low Risk for Developing Hepatocellular Carcinoma?
    20:3, p. 563 - 580 2016
  • Hepatology international
    Thornton Karla, Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment
    10:4, p. 624 - 631 2016
  • Journal of Viral Hepatitis
    Meissner E. G., Achieving Sustained Virologic Response After Interferon-Free Hepatitis C Virus Treatment Correlates with Hepatic Interferon Gene Expression Changes Independent of Cirrhosis
    23:7, p. 496 - 505 2016
  • Gastroenterology (New York, N.Y. 1943)
    Ruane Peter J., 756 Integrated Analysis of Sof+RBV or LDV/Sof for the Treatment of Genotype 4 Chronic HCV Infection
    150:4, p. S1047 - S1048 2016
  • Gastroenterology (New York, N.Y. 1943)
    Flamm Steven, Su1423 Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/Sof) in Treatment-Experienced Cirrhotic Genotype 1 Patients With Chronic Hepatitis C (CHC): A Comparative Analysis of Gilead Sponsored Trials With 4 Real-World Cohorts (RWC)
    150:4, p. S1095 - S1095 2016
  • AIDS Research and Human Retroviruses
    Townsend K., Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration
    32:5, p. 456 - 462 2016
  • Hepatology International
    Petersen T., High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study
    10:2, p. 310 - 319 2016
  • Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America
    Wilson E. M., Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens
    62:3, p. 280 - 288 2016
  • Clinical Advances in Hematology & Oncology
    Kohli Anita, The Relationship between Hepatocellular Carcinoma and Hepatitis B and C Virus
    14:2, p. 96 - 98 2016
  • Expert review of anti-infective therapy
    Nafisi Shirin, Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
    14:1, p. 41 - 56 2016
  • Journal of acquired immune deficiency syndromes (1999)
    Kattakuzhy Sarah, P-B4 Predictors of sustained viral response to 4–6 week duration therapy with Ledipasvir + Sofosbuvir + Gs-9451 +/− Gs-9669 in early and advanced fibrosis (Nih-Ihv synergy trial)
    71:Supplement 1, p. 73 2016
  • Journal of acquired immune deficiency syndromes (1999)
    Wilson Eleanor, P-B11 Retreatment of HCV GT-1 in patients who failed previous short course combination DAA therapy with 12 weeks of LDV/SOF is highly effective
    71:Supplement 1, p. 77 2016
  • AIDS (London, England)
    Townsend K., Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir
    30:2, p. 261 - 266 2016
  • Annals of internal medicine
    Kohli Anita, Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection
    163:12, p. 899 2015
  • The American journal of gastroenterology
    Gill Kirat, A Case of IgG4-Related Disease: A Unique Presentation of a Rare Entity
    110, p. S109 - S110 2015
  • The American journal of gastroenterology
    Khosla Manraj, Recurrent Post-partum Jaundice: Rare Genetic Disorder With Novel Genetic Mutations Identified
    110, p. S397 2015
  • The American journal of gastroenterology
    Gane Edward, Ledipasvir/Sofosbuvir With or Without Ribavirin for the Treatment of Patients With Genotype 2-6 Chronic HCV Infection: Summary Results From Four Phase II Studies
    110, p. S870 - S871 2015
  • Open forum infectious diseases
    Hahn Katherine J., Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment
    2:3, p. ofv091 - ofv091 2015
  • Clinical infectious diseases
    Sidharthan Sreetha, Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials Reply
    61:4, p. 667 - 668 2015
  • The Lancet infectious diseases
    Kohli Anita, Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof of Concept Phase 2a Cohort Study
    15:9, p. 1049 - 1054 2015
  • Clinical infectious diseases
    Sidharthan Sreetha, Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy
    60:12, p. 1743 - 1751 2015
  • Journal of medical virology
    Kohli Anita, Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse
    87:4, p. 544 - 552 2015
  • JAMA : the journal of the American Medical Association
    Hogan John, Virologic response following combined ledipasvir and sofusbuvir administration in patients with HCV genotype 1 and HIV co-infection
    313:12, p. 1232 2015
  • The Lancet (British edition)
    Kohli Anita, Directly Acting Triple Drug Anti-HCV Therapy Induces Sustained Virologic Response with a Six Week Regimen: A Proof of Concept Phase 2a Cohort Study
    385:9973, p. 1107 - 1113 2015
  • JAMA : the journal of the American Medical Association
    Kohli Anita, Assessment of outcomes of hepatitis C treatment--reply
    312:23, p. 2571 - 2571 2014
  • Open forum infectious diseases
    Meissner Eric, LB-4Changes in Intrahepatic, Endogenous Interferon Expression in Chronic HCV, Genotype-1 Patients Treated with Interferon-free, Ribavirin-Free DAA Regimens
    1:suppl_1, p. S67 - S67 2014
  • Annals of internal medicine
    Osinusi Anu, Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse An Open-Label Pilot Study
    161:9, p. 634 - U126 2014
  • SpringerPlus
    Kohli Anita, HCC surveillance results in earlier HCC detection: results from an Indian cohort
    3:1, p. 1 - 5 2014
  • JAMA : the journal of the American Medical Association
    Kohli Anita, Treatment of Hepatitis C A Systematic Review
    312:6, p. 631 - 640 2014
  • AIDS research and human retroviruses
    Shaffer Ashton, Short Communication: Serum-Based Assay Accurately Detects Single Nucleotide Polymorphisms of IL28B and SOCS3 in HIV/Hepatitis C Virus-Coinfected Subjects
    30:8, p. 792 - 795 2014
  • AIDS research and human retroviruses
    Funk Emily K., Short Communication: Interferon/Ribavirin Treatment for HCV Is Associated with the Development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected Patients
    29:9, p. 1190 - 1194 2013
  • JAMA : the journal of the American Medical Association
    Osinusi Anuoluwapo, Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics A Randomized Clinical Trial
    310:8, p. 804 - 811 2013
  • AIDS research and human retroviruses
    Sherman Amy C., Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir
    29:4, p. 665 - 672 2013
  • Journal of acquired immune deficiency syndromes (1999)
    Sidique Nadeera, HIV/HCV-Coinfected Natural Viral Suppressors Have Better Virologic Responses to PEG-IFN and Ribavirin Than ARV-Treated HIV/HCV Patients
    58:2, p. E38 - E40 2011
  • The American journal of tropical medicine and hygiene
    Houpt Eric R, Short report : Asymptomatic Cryptosporidium hominis infection among human immundeficiency virus-infected patients in tanzania
    73:3, p. 520 - 522 2005